Tech Company Inital Public Offerings

Mersana Therapeutics IPO

Mersana Therapeutics, operating out of Cambridge, debuted as a public company on 6/27/2017.

Transaction Overview

Announced On
6/27/2017
Transaction Type
IPO
Amount
$75,000,000
Proceeds Purpose
Proceeds from the IPO will be used as follows: approximately $37.5 million for our Phase 1 clinical trial and ongoing development of XMT-1522, including clinical research outsourcing, drug manufacturing, companion diagnostic development and internal personnel costs; approximately $19.0 million for our preclinical activities and Phase 1 clinical trial of XMT-1536, including clinical research outsourcing, drug manufacturing, companion diagnostic development and internal personnel costs; and approximately $6.0 million for new and ongoing research activities, including for our platform, with the goal of filing one IND every 12 to 24 months.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
840 Memorial Dr.
Cambridge, MA 02139
USA
Email Address
Overview
Mersana Therapeutics, Inc. (NASDAQ: MRSN) is focused on developing novel oncology agents based on Fleximer, a stealth material that enhances the pharmacokinetics and safety of drugs.
Profile
Mersana Therapeutics LinkedIn Company Profile
Social Media
Mersana Therapeutics Company Twitter Account
Company News
Mersana Therapeutics News
Facebook
Mersana Therapeutics on Facebook
YouTube
Mersana Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Anna Protopapas
  Anna Protopapas LinkedIn Profile  Anna Protopapas Twitter Account  Anna Protopapas News  Anna Protopapas on Facebook
Chief Medical Officer
Dirk Huebner
  Dirk Huebner LinkedIn Profile  Dirk Huebner Twitter Account  Dirk Huebner News  Dirk Huebner on Facebook
Chief Scientific Officer
Timothy Lowinger
  Timothy Lowinger LinkedIn Profile  Timothy Lowinger Twitter Account  Timothy Lowinger News  Timothy Lowinger on Facebook
VP - Bus. Development
Eva Jack
  Eva Jack LinkedIn Profile  Eva Jack Twitter Account  Eva Jack News  Eva Jack on Facebook
VP - Finance
Brian DeSchuytner
  Brian DeSchuytner LinkedIn Profile  Brian DeSchuytner Twitter Account  Brian DeSchuytner News  Brian DeSchuytner on Facebook
VP - Manufacturing
Michael Kaufman
  Michael Kaufman LinkedIn Profile  Michael Kaufman Twitter Account  Michael Kaufman News  Michael Kaufman on Facebook


 

 

Browse more venture capital transactions:

Prev: 6/27/2017: Amphivena Therapeutics venture capital transaction
Next: 6/28/2017: Auth0 venture capital transaction

 

Share this article

 


About Our Venture Capital Transactions Database

We do our best to report on every notable VC transaction. VC investment data records on this site are sourced from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary